Home › Sickle Cell Disease › NCT07356050

Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease

Verifying Antibodies After Live Immunization Delivery (VALID): a Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease

Who can join

6 Months – 6 Years · All sexes

Inclusion Criteria:

1. Participants with confirmed Sickle Cell Disease.
2. Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines.
3. Willing and able to provide informed consent
4. Ability to comply with study related evaluations and follow-up visits.

Exclusion Criteria:

1\. Known primary immunodeficiency syndrome, cancer, or acquired immunodeficiency syndrome (AIDS) that would preclude vaccination with live virus vaccines.

About the study

The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)

Sponsor: Children's Hospital Medical Center, Cincinnati · Participants: 130 · Started: Mar 13, 2025

Contact the study team

• Teresa Latham · Phone: 513-803-7922
• Amy Shova · Phone: (513) 803-1917

Official record on ClinicalTrials.gov — NCT07356050

Locations in the U.S.

Conditions

• Sickle Cell Disease

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.